Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Autolus Therapeutics (Nasdaq: AUTL), a biopharmaceutical company focused on programmed T cell therapies, has granted stock options to 60 employees under its 2025 Inducement Plan. The compensation committee approved options to purchase 360,550 shares at an exercise price of $2.47 per share, matching the July 9, 2025 closing price.

The options have a 10-year term with a four-year vesting schedule: 25% vests after one year, followed by monthly vesting over 36 months. These grants were made as inducement awards in accordance with Nasdaq Listing Rule 5635(c)(4).

Positive

• Stock options align employee interests with shareholders
• Structured vesting schedule helps with employee retention

Negative

• Potential future dilution for existing shareholders

LONDON & GAITHERSBURG, Md., July 15, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, today announced that the compensation committee of the Company's Board of Directors granted stock option awards to purchase an aggregate of 360,550 shares of its common stock to 60 employees pursuant to the Company’s 2025 Inducement Plan. The stock options were granted as an inducement material to the individual becoming an employee of Autolus in accordance with Nasdaq Listing Rule 5635(c)(4).

The options have an exercise price of $2.47 per share, which is equal to the closing price of Autolus’ common stock on July 9, 2025. Each option has a ten-year term and vests over four years, with 25% of the original number of shares vesting on the one-year anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter, subject to the employee's continued service with Autolus through the applicable vesting dates.

About Autolus Therapeutics plc
Autolus Therapeutics plc (Nasdaq: AUTL) is an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell therapies and candidates for the treatment of cancer and autoimmune disease. Using a broad suite of proprietary and modular T cell programming technologies, Autolus is engineering precisely targeted and controlled T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and eliminate these cells. Autolus has a marketed therapy, AUCATZYL^®, and a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. For more information, please visit www.autolus.com.

Contact:  

Amanda Cray 
Executive Director, Investor Relations & External Communications
+1 617-967-0207 
a.cray@autolus.com 

FAQ

How many stock options did Autolus Therapeutics (AUTL) grant in July 2025?

Autolus granted stock options to purchase 360,550 shares to 60 employees at an exercise price of $2.47 per share.

What is the vesting schedule for AUTL's July 2025 inducement stock options?

The options vest over 4 years, with 25% vesting after one year and the remainder vesting in 36 equal monthly installments.

What is the exercise price for Autolus Therapeutics' July 2025 inducement grants?

The exercise price is $2.47 per share, equal to AUTL's closing price on July 9, 2025.

How long is the term of AUTL's July 2025 inducement stock options?

The stock options have a ten-year term from the grant date.